Gilead’s Other Products in 3Q17



Gilead’s other products

As discussed earlier, Gilead Sciences’ (GILD) other products include cardiovascular, inflammation, oncology, and respiratory products.

The above chart compares Gilead’s revenue from other products over the last few quarters. Between 3Q16 and 3Q17, revenue from other products fell 1% to $559 million from $564 million.

Cardiovascular drugs

Letairis, Lexiscan, and Ranexa are Gilead’s cardiovascular products. Letairis, a drug approved for the treatment of patients with pulmonary arterial hypertension, witnessed revenue of $213 million in 3Q17, a 1% fall from the $215 million seen in 3Q16. Ranexa, a drug approved for the treatment of patients with chronic angina, saw revenue of $164 million during 3Q17, a 3.5% fall from the $170 million witnessed in 3Q16.

Inflammation and respiratory drugs

Cayston and Tamiflu are Gilead’s inflammation and respiratory drugs. Cayston is a respiratory drug for the treatment of patients with cystic fibrosis and pseudomonas aeruginosa, and Tamiflu is an influenza neuraminidase inhibitor approved for the treatment of patients with influenza infections.

Oncology drugs

Oncology drug Zydelig is approved for use in the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed follicular B-cell non-Hodgkin lymphoma. Zydelig saw revenue of $40 million in 3Q17, marginal growth from the $39 million witnessed in 3Q16.

Other drugs

AmBisome and Macugen are Gilead’s other drugs. In 3Q17, AmBisome saw revenue of $92 million, compared with $91 million in 3Q16. The Vanguard Healthcare ETF (VHT) has a 2.7% exposure to Gilead Sciences (GILD), a 4.0% exposure to AbbVie (ABBV), a 3.6% exposure to Amgen (AMGN), and a 2.6% exposure to Abbott Laboratories (ABT).

More From Market Realist